Navigation Links
Complexities of human disease targeted with $16 million in funding
Date:12/18/2012

Scientists at the Walter and Eliza Hall Institute in Melbourne, Australia, have received more than $16 million in Australian Government funding to pursue research into cancer, malaria, rheumatoid arthritis and the immune system, it was announced today.

The funding was announced by federal health minister Tanya Plibersek and will be distributed through the National Health and Medical Research Council. Walter and Eliza Hall Institute scientists were awarded two program grants, worth more than $15 million over five years, two development grants, worth more than $1.3 million; and three PhD scholarships.

The program grants will:

  • support researchers from the Bioinformatics division as they seek to develop new methods for analysing the massive, complex data sets that are generated by biomedical researchers; and
  • help researchers from the Immunology and Molecular Immunology divisions understand how white blood cells make the decisions that influence the strength, type, and longevity of the immunity created when the body encounters a foreign invader.

Professor Phil Hodgkin, who is leading the immunology research program, said it would focus on the adaptive immune response and the role of B cells and T cells within that response.

"The adaptive immune system is proving one of the most compelling and fascinating in the body," Professor Hodgkin said. "This system underlies our primary defense against acute infection and mediates long-term immunity by generating memory and long-lived effector cells. It is notorious for its complexity.

"Many diseases are associated with dysregulation of the adaptive immune system, including autoimmune conditions, cancer, allergies and immuno-deficiencies. A better understanding of this system would clearly bring health benefits so we will be examining B cell and T cell biology at three levels: the molecular, the cellular, and the whole animal; in the hope of delivering these benefits."

The development grants awarded to the institute will support Dr Chris Burns, who is trying to develop new treatments for rheumatoid arthritis; and Dr Krystal Evans, who is working to develop a new vaccine against the blood stage of the malaria parasite.

Dr Evans said it was estimated that around 3.5 billion people, approximately half of the world's population, live at risk of malaria infection. "There is currently a strong commitment to eliminate malaria in the 21st century. However, it is unlikely that this ambitious goal will be achieved without an effective vaccine," Dr Evans said. "As with smallpox and polio, we believe that a live attenuated vaccine would represent an invaluable tool for malaria elimination."

Dr Evans plans to manufacture a live genetically attenuated parasite blood-stage malaria vaccine, and use it in clinical trials to determine the safety and effectiveness of the vaccine.


'/>"/>
Contact: Penny Fannin
fannin@wehi.edu.au
61-417-125-700
Walter and Eliza Hall Institute
Source:Eurekalert

Related medicine news :

1. Germ in Cat Feces May Affect Human Brain, Behavior: Study
2. New MRI technology to provide even better images of the inside of the human body
3. Mans best friend: Common canine virus may lead to new vaccines for deadly human diseases
4. Pathway identified in human lymphoma points way to new blood cancer treatments
5. Pilot facility launched in Ghana to transform human waste into renewable biodiesel fuel
6. Human Intellect Backsliding From Lack of Evolutionary Pressure: Study
7. Human umbilical cord blood cell co-culture supports embryonic stem cell expansion
8. Sociology, economics researchers receive grant to study development across the human lifespan
9. Gut Bacteria Often Similar in Humans, Chimps: Study
10. First trial in humans of minicells: A completely new way of delivering anti-cancer drugs
11. Testing pain killers on humans could save money and speed the arrival of new drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and ... office, will speak at the American Conference Institute’s 21st Drug & Medical Device ... a Lead Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical ...
(Date:12/2/2016)... ... 2016 , ... Advanced Inc., a leading provider of travel therapy and travel ... serve as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously served ... and operational leadership experience to Advanced Inc. He began his career in finance at ...
(Date:12/2/2016)... PITTSBURGH, PA (PRWEB) , ... December 02, 2016 , ... ... or struggling through rehabilitation of an injury, patients must find the one that works ... for his pain, he created a machine that worked and decided to share it ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research and ... storing, shipping and disposal. The new version is a faster and a more ...
(Date:12/2/2016)... ... 02, 2016 , ... Yisrayl Hawkins, at The House of Yahweh in Abilene, ... into Bible Prophecy. Yisrayl says this generation, known as the Last Generation, started in ... the details line up exactly with Bible Prophecy – a protected way for those ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... YORK , December 2, 2016 ... 5,251.11, down 1.36%; the Dow Jones Industrial Average edged 0.36% ... at 2,191.08, down 0.35%. Losses were broad based as six ... Stock-Callers.com has initiated research reports on the following Services equities: ... (NASDAQ: QGEN ), INC Research Holdings Inc. (NASDAQ: ...
(Date:12/2/2016)... , Dec. 1, 2016 Around the ... country, region and each habitable land present over earth. ... every individual once in a life time this is ... care available until now. Given the steady increase in ... together with the spiraling healthcare costs of treatment, there ...
(Date:12/2/2016)... The iShares Nasdaq Biotechnology Exchange-Traded Fund ... victory early in November. Less political risk has boosted ... predicting an uptick in M&A activities. Today, Stock-Callers.com takes ... they have fared at the last close: Celldex Therapeutics ... (NASDAQ: FOLD ), Navidea Biopharmaceuticals Inc. (NYSE ...
Breaking Medicine Technology: